{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T15:10:20Z","timestamp":1709219420378},"reference-count":93,"publisher":"Wiley","issue":"s5","license":[{"start":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T00:00:00Z","timestamp":1219968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold>Although von Willebrand disease (VWD) has a very long history, our understanding and treatment of the bleeding disorder has only evolved during the past 50\u2003years or so. It was not until the 1920s that VWD was first recognized as a disease separate from that of classical haemophilia. It then took another 30\u2003years before the first effective treatment was developed. Since then, the medical management of VWD has evolved considerably, but not without its ups and downs. One of the key milestones in the evolution of the treatment of VWD was the development of Haemate<jats:sup>\u00ae<\/jats:sup>P\/Humate\u2010P<jats:sup>\u00ae<\/jats:sup>(CSL Behring) \u2013 the first virus\u2010inactivated factor VIII plasma product. For 25\u2003years, this concentrate has demonstrated excellent clinical efficacy and safety for patients with VWD and for those with haemophilia. This article provides an historical overview of the early landmark efforts to ensure a safe plasma\u2010derived replacement product and outlines the clinical evolution in the use of Haemate<jats:sup>\u00ae<\/jats:sup>P.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2008.01847.x","type":"journal-article","created":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T07:56:39Z","timestamp":1219996599000},"page":"3-10","source":"Crossref","is-referenced-by-count":7,"title":["Haemate<sup>\u00ae<\/sup>P von Willebrand factor\/factor VIII concentrate: 25\u2003years of clinical experience"],"prefix":"10.1111","volume":"14","author":[{"given":"W.","family":"SCHRAMM","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,29]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"87","article-title":"Heredit\u00e4r pseudohemofili","volume":"67","author":"Von Willebrand EA","year":"1926","journal-title":"Finska L\u00e4kares\u00e4llskapets Handlingar"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-192803000-00001"},{"key":"e_1_2_7_4_2","first-page":"453","article-title":"\u00dcber ein neues vererbbares Blutungs\u00fcbel: Die konstitutionelle Thrombopathie","volume":"175","author":"Von Willebrand EA","year":"1933","journal-title":"Dtsch Archiv Klin Med"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1957.tb00123.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01630381"},{"key":"e_1_2_7_7_2","first-page":"1307","article-title":"Treatment of hemophilia A and v. Willebrand\u2032s disease","volume":"23","author":"Nilsson IM","year":"1965","journal-title":"Bibl Haematol"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/ort.1965.36.suppl-77.01"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1107180"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.28.8.620"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1976.tb02200.x"},{"key":"e_1_2_7_12_2","first-page":"414","article-title":"Hepatitish\u00e4ufigkeit, HBs\u2010Antigen\u2010 und Anti\u2010HBs\u2010Frequenz bei Patienten des H\u00e4modialysezentrums Heidelberg","volume":"1","author":"Schimpf K","year":"1976","journal-title":"Verh Dtsch Ges Inn Med"},{"key":"e_1_2_7_13_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.1977.tb01513.x","article-title":"Modifications of factor VIII related antigen in hemophiliacs with acute hepatitis and sub\u2010clinical liver disease","volume":"30","author":"Sultan Y","year":"1977","journal-title":"Scand J Haematol Suppl"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0609.1977.tb01512.x","article-title":"Jaundice and hepatitis B surface antigen and antibody in Greek haemophiliacs","volume":"30","author":"Yannitsiotis A","year":"1977","journal-title":"Scand J Haematol Suppl"},{"key":"e_1_2_7_15_2","first-page":"165","article-title":"Faktor VIII\u2010Konzentrat \u2013 hepatitissicher: Fortschritte in der Behandlung der H\u00e4mophilie A","volume":"4","author":"Heimburger N","year":"1980","journal-title":"Gelben Hefte"},{"key":"e_1_2_7_16_2","first-page":"621","article-title":"Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates","volume":"36","author":"Hilfenhaus J","year":"1986","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_17_2","first-page":"619","article-title":"Faktor VIII\u2010Konzentrat, hochgereinigt und in L\u00f6sung erhitzt","volume":"31","author":"Heimburger N","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(02)00044-0"},{"key":"e_1_2_7_19_2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0038-1648406","article-title":"Prevention of hepatitis C virus infection in children with haemophilia A and B and von Willebrand\u2019s disease","volume":"67","author":"Kreuz W","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_20_2","first-page":"303","article-title":"Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients","volume":"67","author":"Heimburger N","year":"1987","journal-title":"Dev Biol Stand"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161505"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30198"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30195"},{"key":"e_1_2_7_24_2","first-page":"164","volume-title":"21es H\u00e4mophilie\u2010Symposion Hamburg 1990","author":"Kreuz W","year":"1990"},{"issue":"1","key":"e_1_2_7_25_2","first-page":"A49","article-title":"Anti\u2010HCV prevalence in children with haemophilia and other coagulation disorders \u2013 results of the first and second generation test","volume":"66","author":"Kreuz W","year":"1993","journal-title":"Ann Hematol"},{"issue":"1","key":"e_1_2_7_26_2","first-page":"24","article-title":"15\u2003years experience with virus safety of pasteurized factor VIII concentrates in Germany","volume":"2","author":"Pollmann H","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_7_27_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1055\/s-0038-1653858","article-title":"Hepatitis C and pasteurised factor VIII and IX concentrates","volume":"73","author":"Klarmann D","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-178-42045"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1986.tb04882.x"},{"key":"e_1_2_7_30_2","first-page":"337","article-title":"Inactivation of HTLV\u2010III\/LAV, hepatitis B and non\u2010A\/non\u2010B viruses by pasteurization in human plasma protein preparations","volume":"67","author":"Mauler R","year":"1987","journal-title":"Dev Biol Stand"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198910263211702"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93050-B"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30197"},{"issue":"3","key":"e_1_2_7_34_2","first-page":"137","article-title":"Human parvovirus B19 is inactivated by pasteurization, a dedicated virus reduction step in the manufacturing procedure of plasma derivatives","volume":"10","author":"Sch\u00e4fer W","year":"2004","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_7_35_2","first-page":"6","article-title":"Removal of prions by the manufacturing process of the VWF\/FVIII coagulation concentrate Haemate P\/Humate P","volume":"12","author":"Sch\u00e4fer W","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00319766"},{"key":"e_1_2_7_37_2","first-page":"231","article-title":"Comparison between cryoprecipitate and a wet treated\u2010factor VIII concentrate in the treatment of von Willebrand\u2019s disease","volume":"16","author":"Scharrer I","year":"1986","journal-title":"Ric Clin Lab"},{"key":"e_1_2_7_38_2","first-page":"353","article-title":"Heat\u2010treated factor VIII\/von Willebrand factor concentrate in platelet\u2010type von Willebrand\u2019s disease","volume":"17","author":"Takahashi H","year":"1987","journal-title":"Haemostasis"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00825.x"},{"key":"e_1_2_7_40_2","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood.V72.3.1100.bloodjournal7231100","article-title":"Humate\u2010P for treatment of von Willebrand disease","volume":"72","author":"Czapek EE","year":"1988","journal-title":"Blood"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320748"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1989.tb02031.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00893.x"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.0050s2060.x"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050184"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830310108"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb00227.x"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3025.x"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613027"},{"issue":"1","key":"e_1_2_7_51_2","first-page":"P1667","article-title":"Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF\u2010collagen\u2010binding\u2010assays in VWF\/FVIII\u2010concentrates","volume":"1","author":"Suiter T","year":"2003","journal-title":"J Thromb Haemost"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2003.tb05768.x"},{"key":"e_1_2_7_53_2","first-page":"298","article-title":"Experience with Haemate P in von Willebrand\u2019s disease in adults","volume":"24","author":"Scharrer I","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30490273452.x"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61203-8"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1992.tb01198.x"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-994004"},{"key":"e_1_2_7_58_2","first-page":"304","article-title":"Haemate P in children with von Willebrand\u2019s disease","volume":"24","author":"Kreuz W","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022215100130373"},{"key":"e_1_2_7_60_2","first-page":"513","article-title":"Report of the efficacy and safety of Haemate P in Canadian von Willebrand disease (vWD) patients","volume":"77","author":"Blanchette V","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_61_2","first-page":"514","article-title":"Successful cardiac surgery in a young girl with type 2a von Willebrand disease using continuous infusion of Haemate\u2010P","volume":"77","author":"Naqvi A","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.00198.x"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x"},{"key":"e_1_2_7_64_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.0050s2064.x"},{"key":"e_1_2_7_65_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0037-1614448","article-title":"Safety and efficacy of continuous infusion of a combined factor VIII\u2010von Willebrand factor (vWF) concentrate (Haemate\u2010P) in patients with von Willebrand disease","volume":"81","author":"Lubetsky A","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00341.x"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10074"},{"issue":"1","key":"e_1_2_7_68_2","first-page":"145","article-title":"Continuous infusion of factor VIII after elective surgery in children with haemophilia A and von Willebrand disease","volume":"2","author":"Auerswald G","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_7_69_2","first-page":"191","article-title":"Kontinuierliche Infusion von Faktoren\u2010Konzentraten nach Operation bei Kindern mit H\u00e4mophilie","volume":"37","author":"Auerswald G","year":"1997","journal-title":"Gelben Hefte"},{"key":"e_1_2_7_70_2","first-page":"183","article-title":"Stabilit\u00e4t von Faktor VIII\u2010Pr\u00e4paraten: Voraussetzung f\u00fcr die kintinuierliche Infusion","volume":"37","author":"Metzner HJ","year":"1997","journal-title":"Gelben Hefte"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1080\/088800199276859"},{"key":"e_1_2_7_72_2","first-page":"226","article-title":"Continuous infusion of pdFVIII during and after elective surgery in 13 patients with von Willebrand\u2019s disease type 3","volume":"6","author":"Auerswald G","year":"2000","journal-title":"Haemophilia"},{"issue":"3","key":"e_1_2_7_73_2","first-page":"12","article-title":"Stability of the VWF\/FVIII concentrate Haemate P\/Humate P after reconstitution: influences on VWF multimers, VWF:RCo, VWF:CB, FVIII and FVIII\u2010binding activities","volume":"10","author":"Walter O","year":"2004","journal-title":"Haemophilia"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01836069"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90109-N"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3007.x"},{"key":"e_1_2_7_77_2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1055\/s-0037-1615752","article-title":"Pharmacokinetic studies with FVIII\/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome","volume":"85","author":"Luboshitz J","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_78_2","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand factor concentrate (Haemate\u2010P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand\u2019s disease","volume":"88","author":"Franchini M","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612977"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200406000-00006"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_7_83_2","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V106.11.1781.1781","article-title":"Treatment of VWD patients requiring elective surgery with a pasteurized von Willebrand Factor\/FVIII concentrate (Haemate\u00aeP)\u2010the use of a PK guided approach","volume":"106","author":"Mannucci PM","year":"2005","journal-title":"Blood"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167659.23262.18"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01184.x"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00036.x"},{"issue":"4","key":"e_1_2_7_87_2","first-page":"16","article-title":"Immune tolerance induction (ITI) in haemophilia A \u2013 patients with inhibitors \u2013 the choice of concentrate affecting success","volume":"86","author":"Kreuz W","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_7_88_2","first-page":"EREP05","article-title":"The role of plasma\u2010derived factor VIII\/von Willebrand factor concentrates in the treatment of hemophilia A patients","volume":"88","author":"Auerswald G","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_7_89_2","first-page":"A85","article-title":"Successful immune tolerance therapy of FVIII\u2010inhibitor in children after changing from high to intermediate purity FVIII concentrate","volume":"72","author":"Kreuz W","year":"1996","journal-title":"Ann Hematol"},{"key":"e_1_2_7_90_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-80403-8_25"},{"key":"e_1_2_7_91_2","article-title":"Epidemiology of inhibitors and current treatment strategies","volume":"88","author":"Kreuz W","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00022.x"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650655"},{"key":"e_1_2_7_94_2","first-page":"3","article-title":"The factor VIII\/von Willebrand factor complex: basic and clinical issues","volume":"88","author":"Federici AB","year":"2003","journal-title":"Haemotologica"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2008.01847.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2008.01847.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T14:38:08Z","timestamp":1709217488000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2008.01847.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,29]]},"references-count":93,"journal-issue":{"issue":"s5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2516.2008.01847.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2008.01847.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,29]]}}}